Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 20Carcinoma, Non-Small-Cell Lung 15Urinary Bladder Neoplasms 13Lung Neoplasms 13Ovarian Neoplasms 9Non-Muscle Invasive Bladder Neoplasms 6Cholangiocarcinoma 6Neoplasm Metastasis 5Colorectal Neoplasms 5Biliary Tract Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Lymphoma, Large B-Cell, Diffuse 4Fallopian Tube Neoplasms 4Breast Neoplasms 4Triple Negative Breast Neoplasms 3Osteosarcoma 3Nasopharyngeal Carcinoma 3Melanoma 3Endometrial Neoplasms 3Carcinoma, Transitional Cell 3Recurrence 2Rectal Neoplasms 2Lymphoma, Follicular 2Gallbladder Neoplasms 2Colonic Neoplasms 2Bile Duct Neoplasms 2Uterine Cervical Neoplasms 1Urothelial Cancer 1Urologic Neoplasms 1Stomach Neoplasms 1

Interventions

Tretinoin 2Carboplatin 2durvalumab 1Pemetrexed 1Paclitaxel 1Gemcitabine 1Cisplatin 1Azacitidine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Complete Response × Gemcitabine × 30 days × Clear all
NCT06694454 2026-06-04

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡